Contact: Nancy Morter
Dilon Diagnostics
C: 757-589-3914
O: 757-269-4910 x 302
E: nfmorter@dilon.com

Dilon Diagnostics® Partners with PenRad®

Collaboration for delivery of advanced diagnostic imaging and information management solutions

NEWPORT NEWS, VA, AUGUST 23, 2011 - Dilon expands its portfolio of breast imaging solutions through a sales alliance with PenRad, rated #1 Mammography Information System technology by KLAS for three consecutive years. Product innovation, high quality and customer loyalty are the foundation of PenRad's success. Together Dilon and PenRad provide leading-edge breast imaging tools, and an information management system that significantly improves patient care, mammography workflow and imaging center economics.

Dilon Diagnostics, recipient of the Frost & Sullivan Molecular Breast Imaging Company of 2011 and the KLAS category winner for Breast Specific Imaging Modalities 2010, is the market leader for compact gamma cameras that support breast-specific gamma imaging/molecular breast imaging (BSGI/MBI) studies. Dilon optimizes the clinical results of BSGI/MBI, a procedure that sees lesions independent of tissue density and provides a functional imaging complement to the anatomical imaging of mammography. BSGI/MBI is particularly useful for patients with equivocal mammograms, dense breast tissue and for help with determining the extent of disease.

With camera installations worldwide, Dilon is now expanding its portfolio in women's imaging to include the PenRad Mammography Information System (MIS), and Volpara, a quantitative breast density assessment tool that converts the qualitative breast x-ray image into quantitative data. Breast tissue density has not only been linked to an increased risk of breast cancer, it also decreases the sensitivity of the mammogram and thereby may impact early detection. Volpara is designed to assist radiologists by objectively and automatically assessing a woman's breast density, and facilitates breast centers' compliance with new legislation and notification guidelines. PenRad automatically integrates the information from Volpara and BSGI/MBI into the routine MIS workflow.

PenRad has been pioneering the technological advancement of mammography information systems (MIS) for 15 years, increasing professional productivity, reducing costs and enhancing patient care. Greg Gustafson, president of PenRad, notes that the company has grown exponentially on the guiding principles of continually enhancing a customer's clinical and financial value, and setting the market expectations for service and ongoing support.

CEO of Dilon Diagnostics, Robert G. Moussa said that "Dilon's expanded suite of PenRad MIS products align well with our global strategy of providing diagnostic solutions with the most sophisticated technological platforms. Our vision is to provide patients and physicians around the world with superior, cost-effective and healthcare solutions that provide the greatest opportunity for early diagnosis and intervention for breast cancer."

About PenRad

Founded in 1995, PenRad's suite of products provides a complete solution to enhance workflow, quality and revenue in image and information management. Designed flexible and for easy integration, PenRad products include a web-based multi-modality workstation, computer-aided visualization and analysis for MRI and CAD for ultrasound, and information systems for fast and reliable interpretation, reporting, tracking and management of clinical data. Whether integrating with existing infrastructure or providing a complete solution, PenRad partners with customers to optimize workflow. PenRad MIS is the KLAS 2010 MIS Category Leader -- third consecutive year.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to the global medical marketplace. Dilon's cornerstone product, the Dilon 6800, is a digital high-resolution, compact gamma camera optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake, indicating the presence or absence of cancer. Many leading medical centers around the world are now offering BSGI to their patients, including: Cornell University Medical Center, New York; The George Washington University Medical Center, Washington, D.C.; and the Hôtel Dieu, Paris, France. For more information on Dilon Diagnostics please visit www.dilon.com.

####